Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (2163)	11/10/2008 5:56:28 PM
From: Ian@SI	Read Replies (2) \| Respond to of 3661

I suspect that the corporate culture that caused this PR to be created AND issued is also the root cause of an almost certainly completely worthless entity making it into 3 Phase 2 studies. ++++++++++++++++++++++++++++++++++ Co announces top-line data from its SB-509-601 clinical trial, one of SGMO's three Phase 2 clinical studies from its ZFP Therapeutic program to develop SB-509 for diabetic neuropathy. The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in a number of measures of nerve function and health at the primary analysis point, day 180 post-treatment.